

CIDP Disease Burden — Results of a US Nationwide Patient Survey

Jeffrey A. Allen,¹ Lisa Butler,² Todd D. Levine,³ Ann L. Bullinger⁴ and Carol L. Koski²

¹Department of Neurology, University of Minnesota, Minneapolis, MN, USA.
²GBS|CIDP Foundation International, Conshohocken, PA, USA.
³Phoenix Neurological Associates, Phoenix, AZ, USA.
⁴CSL Behring, King of Prussia, PA, USA.

Introduction

- Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare peripheral neuropathy characterized by upper and lower limb weakness, and sensory and reflex loss^{1,2}

CIDP DISEASE BURDEN

- CIDP is most frequently treated with intravenous immunoglobulin (IVIg) or corticosteroids; but patients may still report symptoms such as pain, fatigue, and a multitude of personal and professional limitations³⁻⁵
- Treatment with IVIg commonly requires lengthy infusions which can result in missing time from work or school

US PATIENT SURVEY

- A nationwide survey of US CIDP patients was conducted to assess the impact of disease-related disability and treatment on lifestyle and work activities

Aim

- To assess the impact of CIDP disease-related disability and treatment on domestic arrangements and work activities through a nationwide survey of US CIDP patients

Methods


- Approximately 3250 individuals aged ≥18 years, recruited by the GBS|CIDP Foundation and self-reported to have CIDP, were invited to complete an online survey; of these, 475 completed the survey and their responses were used to assess disease and treatment burden

Results

AGE AT DIAGNOSIS

- Three-in-ten were diagnosed with CIDP between the ages of 50–59 (Figure 1)
- Those with CIDP were rarely diagnosed before the age of 30


Figure 1: Age of those with CIDP at official diagnosis



TIME BETWEEN SYMPTOM RECOGNITION AND CIDP DIAGNOSIS

- The time between symptom recognition and diagnosis varied widely amongst patients (Figure 2)
- Just under two-in-five noticed their symptoms a year or more before receiving their official diagnosis


Figure 2: Length of time between noticing symptoms and initial CIDP diagnosis



MOST BOTHERSOME SYMPTOMS WHEN MEDICATION STARTED

- The most bothersome symptoms at the time of starting treatment stratified by likelihood of CIDP diagnosis are shown in Figure 3
- Around half indicated loss of balance/coordination as one of the top three most bothersome symptoms at the start of treatment
- Pain, weakness and numbness were also commonly indicated


Figure 3: Most bothersome symptoms at the time of starting medication



GENERAL DISEASE BURDEN

- A summary of the impact of CIDP on professional life, living circumstances, mobility, and quality of life is shown in Figure 4


Figure 4: Summary of general CIDP disease burden



IMPACT ON WORK OR SCHOOL

- Overall, 20% of respondents reported missing time from work or school due to CIDP symptoms; Figure 5A shows these 20% stratified by number of days missed
- Of respondents currently on IVIg therapy, 28% reported missing time from work or school due to infusions; Figure 5B shows these 28% stratified by number of days missed

Figure 5: Time missed from work or school in the past month



Conclusion

- The results from this US nationwide survey demonstrate that both CIDP and commonly prescribed CIDP treatments are associated with disease and treatment burdens that impact school, work, and home activities

References

- Mathey EK, et al. *J Neurol Neurosurg Psychiatry*. 2015; **86**:973-985.
- Dalakas MC. *Nat Rev Neurol*. 2011; **7**:507-517.
- Santos PL, et al. *Arq Neuropsiquiatr*. 2014; **72**:179-183.
- Merkies IS, et al. *Eur Neurol*. 2016; **75**:199-206.
- Merkies IS, et al. *Neurology*. 1999; **53**:1648-1654.

Editorial assistance was provided by Meridian HealthComms.

Many thanks to all who participated in the survey, especially to those who donated their gift back to the Foundation!